Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma is an incurable plasma cell malignancy requiring novel therapies.
• Thalidomide has emerged as a promising agent for myeloma treatment.
• Current systemic and supportive therapies have limitations.

Purpose of the Study:

• To evaluate the efficacy and tolerability of thalidomide in multiple myeloma.
• To assess thalidomide's safety profile in a compassionate use setting.
• To determine response rates and survival outcomes for thalidomide-treated patients.

Main Methods:

• Retrospective analysis of 21 consecutive multiple myeloma patients.
• Patients received thalidomide alone or in combination with dexamethasone and/or cyclophosphamide.
• Therapy administered as first-line, maintenance, or salvage treatment.

Main Results:

• Overall response rate of 61.9% observed, with higher rates for combination therapy (77.8%).
• Median progression-free survival was 20 months.
• Low-dose thalidomide (50-150 mg/day) was generally well-tolerated, with neurotoxicity managed by dose reduction.

Conclusions:

• Low-dose thalidomide (50-100 mg/day) is a safe and effective therapy for multiple myeloma.
• Thalidomide demonstrates efficacy in patients with refractory, relapsed, or indolent disease.
• Combination therapy with thalidomide shows promising results in multiple myeloma treatment.